Axa
ZNTL icon

Axa’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Axa’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-228,827
Closed -$4.96M – 1229
2022
Q3 		$4.96M Buy
228,827
+985
+0.4% +$26.9K 0.02% 578
2022
Q2 		$6.4M Buy
227,842
+94,449
+71% +$2.5M 0.02% 523
2022
Q1 		$6.15M Buy
133,393
+1
+0% +$54 0.02% 591
2021
Q4 		$11.2M Buy
133,392
+1,591
+1% +$123K 0.03% 462
2021
Q3 		$8.78M Buy
131,801
+4,856
+4% +$280K 0.02% 535
2021
Q2 		$6.75M Sell
126,945
-37,067
-23% -$1.99M 0.02% 634
2021
Q1 		$7.12M Buy
164,012
+3,042
+2% +$131K 0.02% 609
2020
Q4 		$8.36M Buy
160,970
+4,883
+3% +$220K 0.03% 564
2020
Q3 		$5.1M Buy
156,087
+49,444
+46% +$1.73M 0.02% 617
2020
Q2 		$5.12M Buy
+106,643
New +$4.09M 0.02% 606

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Axa's ZNTL Position: Q4 2022 in Review

Axa sold out of Zentalis Pharmaceuticals (ZNTL) in Q4 2022, closing a stake of 228,827 shares — an estimated $4.96M sold.

Axa first reported a position in ZNTL in Q2 2020 and held it in 10 quarters. The position peaked at $11.2M in Q4 2021. 106 funds tracked by Wall St. Rank hold ZNTL as of Q4 2022.

  • Axa reported no remaining Zentalis Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Axa sold 228,827 Zentalis Pharmaceuticals shares in Q4 2022, an estimated $4.96M.
  • Axa first reported a position in Zentalis Pharmaceuticals in Q2 2020 and held it in 10 quarters.
  • Axa's Zentalis Pharmaceuticals position peaked at $11.2M in Q4 2021.
  • 106 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q4 2022.

Based on Axa's 13F filing for Q4 2022, filed 14 Feb 2023.